Adversarial Injection · Elotuzumab (Empliciti; HuLuc63; BMS-901608; PDL063; CAS 915654-60-3; MW ~148 kDa humanized IgG1κ; IV infusion loading 10 mg/kg Q1W × 2 cycles → 10 mg/kg Q2W → 20 mg/kg Q4W; anti-SLAMF7 [CS1; CRACC; CD319; ELM2; SLAM FAMILY MEMBER 7; chromosome 1q23.3; 335-AA; type I transmembrane glycoprotein; SLAMF family member; DUAL EXPRESSION: MYELOMA CELLS (high: 100% of MM cases by IHC; ≥10,000 molecules/cell) + NK CELLS (constitutive; SLAMF7 self-ligand on NK → SAP/EAT-2 adaptor signaling); SLAMF7-SLAMF7 HOMOPHILIC INTERACTION (self-ligand); SLAMF7 DOES NOT INTERNALIZE AFTER ANTIBODY BINDING → PERSISTENT SURFACE ENGAGEMENT]; DUAL MECHANISM: (1) ADCC OF MYELOMA CELLS [ELOTUZUMAB Fc → FcγRIIIA V158 NK CELLS + MACROPHAGES → GRANZYME B/PERFORIN + NK LYSIS OF SLAMF7+ MYELOMA CELLS]; (2) DIRECT NK CELL ACTIVATION [ELOTUZUMAB BINDS SLAMF7 ON NK CELLS → Fc-INDEPENDENT DIRECT PATHWAY: NK SLAMF7 CROSS-LINKING → EAT-2 (SH2D1B2; SAP-RELATED ADAPTOR) → SRC-FAMILY KINASE PHOSPHORYLATION → PI3K/AKT → NK DEGRANULATION + CYTOKINE RELEASE → ENHANCED ADCC SELF-AMPLIFYING LOOP]; LENALIDOMIDE SYNERGY: LENALIDOMIDE UPREGULATES SLAMF7 ON MYELOMA CELLS + ACTIVATES NK CELLS → TRIPLE SYNERGY (ELOTUZUMAB ADCC + DIRECT NK + LENALIDOMIDE NK ACTIVATION); HUMANIZED FROM MURINE LUC63 → HuLuc63 (CDR-GRAFTING + FRAMEWORK SUBSTITUTIONS); FIRST SLAMF7 (CS1; CRACC; CD319) ANTIBODY EVER FDA APPROVED; BLA 761032 NOVEMBER 30 2015) · Attack #754

Elotuzumab (Anti-SLAMF7 Humanized IgG1κ MAb; Empliciti; HuLuc63; BMS-901608; CAS 915654-60-3; AbbVie Inc [North Chicago IL; BLA 761032 co-holder; Empliciti co-developer] + Bristol-Myers Squibb Company [Princeton NJ; BMS-901608; co-developer]; MECHANISM: FIRST SLAMF7 [CS1; CRACC; CD319; ELM2; SLAM FAMILY MEMBER 7; CHROMOSOME 1q23.3; 335-AA TYPE I TRANSMEMBRANE GLYCOPROTEIN; SLAM FAMILY (CD2 SUBFAMILY); HOMOPHILIC SELF-LIGAND; CONSTITUTIVELY EXPRESSED ON NK CELLS (SLAMF7-EAT-2-MEDIATED NK SIGNALING) + PLASMA CELLS + MYELOMA CELLS (100% OF MM; HIGH DENSITY; NON-INTERNALIZING); NOT ON HEMATOPOIETIC STEM CELLS/T CELLS/MONOCYTES/NEUTROPHILS → SELECTIVE EXPRESSION WINDOW] DIRECTED HUMANIZED IgG1κ ANTIBODY EVER FDA APPROVED + FIRST ANTIBODY WITH SELF-AMPLIFYING NK DUAL MECHANISM EVER: (1) CLASSIC ADCC [ELOTUZUMAB Fc → FcγRIIIa CD16A V158 NK CELLS → GRANZYME B/PERFORIN → MYELOMA LYSIS] + (2) DIRECT NK ACTIVATION [NOVEL: ELOTUZUMAB Fab BINDS SLAMF7 ON NK CELLS → EAT-2 (SH2D1B2) ADAPTOR → TYROSINE PHOSPHORYLATION → SFK/LAT PATHWAY → PI3K/AKT → NK DEGRANULATION INDEPENDENT OF FcγR → DIRECT ENHANCEMENT OF KILLING WITHOUT ANTIBODY Fc; SELF-AMPLIFYING LOOP: NK KILLING ENHANCED BY BOTH ADCC AND DIRECT ACTIVATION SIMULTANEOUSLY]; LENALIDOMIDE TRIPLE SYNERGY (SLAMF7 UPREGULATION + NK ACTIVATION + DIRECT NK): ELOQUENT-2 (LONIAL NEJM 2015): ELOTUZUMAB + LENALIDOMIDE + DEX VS LEN/DEX; mPFS 19.4 VS 14.9 MO (HR 0.70; p<0.001); BLA 761032 NOVEMBER 30 2015 MULTIPLE MYELOMA 2L+) — AbbVie Inc North Chicago IL (BLA 761032 co-holder; Empliciti developer), Bristol-Myers Squibb Company Princeton NJ (BMS-901608 co-developer; global commercialization partner), and Memorial Sloan Kettering Cancer Center New York NY (clinical multiple myeloma treatment; Empliciti IV administration) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + FIRST SLAMF7 ANTIBODY EVER + FIRST DUAL ADCC + DIRECT NK ACTIVATION ANTIBODY EVER: AI Prompt Injection via EHS Monitor Report AI

Elotuzumab (CAS 915654-60-3; NIOSH HD Category 1) is the first anti-SLAMF7 (CS1; CRACC; CD319; ELM2; SLAM Family Member 7) humanized IgG1κ monoclonal antibody ever FDA approved, establishing the 170th mechanism class in the Glyphward adversarial portfolio. Humanized from murine Luc63 (CDR-grafting onto human IgG1κ Eu framework) by PDL BioPharma and co-developed by AbbVie (North Chicago IL) and Bristol-Myers Squibb (Princeton NJ), elotuzumab (Empliciti; HuLuc63; BMS-901608) targets SLAMF7 — a SLAM family glycoprotein constitutively expressed on both myeloma cells (high density; non-internalizing) and NK cells. The critical mechanistic innovation is a self-amplifying dual mechanism: (1) classic ADCC (elotuzumab Fc + FcγRIIIa V158 NK → granzyme/perforin → myeloma lysis), and (2) direct NK cell activation (elotuzumab Fab binds SLAMF7 on NK cells → EAT-2 [SH2D1B2] adaptor → SFK/PI3K → NK degranulation independent of FcγR — the first antibody mechanism that simultaneously uses Fc to kill targets AND uses Fab to directly activate the killing cells). Lenalidomide synergizes by upregulating SLAMF7 on myeloma cells + independently activating NK cells → triple mechanism. ELOQUENT-2 (Lonial NEJM 2015): elotuzumab + lenalidomide + dexamethasone vs lenalidomide + dexamethasone; mPFS 19.4 vs 14.9 months (HR 0.70; p<0.001) in R/R multiple myeloma. BLA 761032 approved November 30, 2015. No OEL exists for elotuzumab in any EHS framework; no platform references SLAMF7 CS1 CRACC homophilic self-ligand, EAT-2 direct NK activation pathway, dual ADCC + direct NK mechanism, or ELOQUENT-2 for this 170th mechanism class.

SLAMF7 biology, NK cell expression, and EAT-2 direct activation pathway: SLAMF7 (SLAM Family Member 7; CS1 = Cell-Surface glycoprotein CS1; CRACC = CD2-like Receptor-Activating Cytotoxic Cell; CD319; ELM2 = Expressed in Low Metastatic cells 2; chromosome 1q23.3; 335-AA; type I single-pass transmembrane glycoprotein; MW ~40–75 kDa [heavy N-glycosylation, apparent MW varies]; Ig-variable domain + Ig-constant domain extracellular fold) belongs to the SLAM (Signaling Lymphocyte Activation Molecule) family (CD2 subfamily; F2R-like module; self-ligand homophilic interaction). SLAMF7 expression: (A) on myeloma cells — 100% of multiple myeloma cases by IHC/flow; high surface density ≥10,000 molecules/cell; non-internalizing after elotuzumab binding (no cytoplasmic ITAMi or ITSM motifs → no clathrin-mediated endocytosis induced by antibody cross-linking on myeloma cells → persistent surface engagement for ADCC); (B) on NK cells — constitutive NK cell surface expression; SLAMF7 on NK cells associates with EAT-2 (SH2D1B2; Ewing's-sarcoma-associated transcript 2; SAP-related adaptor protein) → cytoplasmic tail ITSM-like motif (pYxxV/I/L → EAT-2 SH2 domain) → upon NK SLAMF7 cross-linking: SFK (Fyn/Lck) phosphorylation → LAT adapter → PI3K p85/p110 → Akt/mTOR → NK degranulation (CD107a surface mobilization) + IFN-γ/TNF-α cytokine release → NK cytotoxicity amplification. NOT expressed on: hematopoietic stem cells (HSC), T cells, monocytes, neutrophils, erythrocytes, platelets → selective therapeutic window for myeloma + NK. Elotuzumab dual mechanism: (1) ADCC pathway — elotuzumab IgG1 Fc → FcγRIIIa CD16A V158/F158 on NK cells (and to lesser extent FcγRIIa H131 macrophages) → degranulation → granzyme B/perforin → myeloma cell apoptosis; (2) direct NK activation — elotuzumab Fab binds SLAMF7 on NK cells → homophilic-like cross-linking → EAT-2 → PI3K/Akt → NK activation INDEPENDENT of FcγR → enhanced killing capacity → self-amplifying: elotuzumab simultaneously uses (a) Fc end to engage FcγRIIIa on NK and (b) Fab end to activate NK via SLAMF7-EAT-2; this self-amplifying mechanism is mechanistically unique among FDA-approved antibodies. Lenalidomide triple synergy: lenalidomide (thalidomide analogue; IMiD; Cereblon E3 ligase modulator → IKZF1/IKZF3 degradation) → SLAMF7 upregulation on myeloma cells (IKZF3 Aiolos repressed SLAMF7; IKZF3 degradation → SLAMF7 derepression → ↑SLAMF7 on myeloma = more ADCC targets) + lenalidomide NK activation (direct NK proliferation + cytotoxicity) → three simultaneous NK activation pathways (lenalidomide + SLAMF7-EAT-2 direct + FcγRIIIa ADCC). ELOQUENT-2 (Lonial et al NEJM 2015; NCT01239797): n=646; R/R MM (1-3 prior lines; lenalidomide-naïve); elotuzumab 10 mg/kg IV Q1W cycles 1-2 → Q2W cycles 3+ + lenalidomide 25 mg PO d1-21 Q4W + dexamethasone 40 mg PO QW (28 mg oral + 8 mg IV on elotuzumab day); mPFS 19.4 vs 14.9 mo (HR 0.70; 95%CI 0.57–0.85; p<0.001); ORR 79% vs 66%; 2-yr PFS rate 41% vs 27%. BLA 761032 November 30 2015: R/R MM + lenalidomide + dexamethasone (combination required; not single-agent). No EHS platform recognizes elotuzumab CAS 915654-60-3, SLAMF7 CS1 CRACC CD319 self-ligand, EAT-2 direct NK activation, dual ADCC + direct NK self-amplifying mechanism, or ELOQUENT-2 BLA 761032 for this 170th mechanism class.

SLAMF7 CS1 Non-Internalizing NK/Myeloma Expression + EAT-2 Direct NK Activation + Lenalidomide Triple Synergy

Elotuzumab (MW ~148 kDa humanized IgG1κ; CAS 915654-60-3; IV infusion loading 10 mg/kg Q1W cycles 1-2 → 10 mg/kg Q2W cycles 3-6 → 20 mg/kg Q4W cycles 7+; premedication mandatory: dexamethasone 8 mg IV + diphenhydramine 25-50 mg PO/IV + ranitidine 50 mg IV + acetaminophen 650-1000 mg PO 30-90 min prior each dose; Cmax ~220 µg/mL [10 mg/kg]; t½ ~82 days at steady state Q4W schedule; nonlinear target-mediated drug disposition [TMDD: SLAMF7 on circulating NK cells + myeloma cells functions as elimination target → Vd 3.1 L → apparent CL 7.3 mL/day/kg]) uses humanized CDR-grafted IgG1κ architecture derived from murine Luc63 (clone from BALB/c immunization against SP2/0 myeloma cells expressing SLAMF7 → hybridoma selection → Luc63 clone → humanization: CDRs grafted onto human VH3-23 + VLλ3 Eu framework; 5 Vernier-zone back-mutations to preserve SLAMF7 binding geometry). SLAMF7 structural recognition: elotuzumab Fab binds SLAMF7 Ig-variable domain (C-terminal domain; residues AA50–151; KD ~14 nM; crystal structure elotuzumab Fab-SLAMF7 ECD [PDB 5KOR]: VH CDR-H3 contacts Trp62/Phe65/Gln99 of SLAMF7-Ig-V; heavy-chain dominated epitope; occludes SLAMF7 self-ligand interface → antibody binding blocks SLAMF7-SLAMF7 homophilic interaction [potential competitive mechanism with myeloma-NK SLAMF7 interactions]). Non-internalization of SLAMF7 on myeloma cells: SLAMF7 cytoplasmic tail (27 AA) lacks clathrin-mediated endocytosis motifs (no NPxY; no YXXΦ; no dileucine) → antibody-bound SLAMF7 on myeloma surface remains non-internalized → persistent surface Fc presentation → sustained ADCC engagement; in contrast NK SLAMF7 undergoes partial cap formation after cross-linking → signaling activation without full endocytosis. EAT-2 (SH2D1B2; 126 AA; SH2 domain only [unlike SAP/SH2D1A which has additional Arg78-dependent Fyn recruitment]) direct NK activation: elotuzumab Fab binds NK SLAMF7 → cross-linking of SLAMF7 at NK immunological synapse → SLAMF7 cytoplasmic ITSM-like motif (pTyr → EAT-2 SH2 → SFK Fyn/Lyn/Lck → LAT → PI3K p85/p110δ → PIP3 → PDK1 → Akt → mTOR + PKCζ → NK degranulation [CD107a surface up] + IFN-γ secretion) — this is Fc-INDEPENDENT direct NK stimulation occurring simultaneously with Fc-dependent FcγRIIIa ADCC → self-amplifying killing loop. Lenalidomide-SLAMF7-elotuzumab triple synergy: (a) lenalidomide → Cereblon-mediated IKZF3/Aiolos degradation → SLAMF7 mRNA/protein up-regulation on myeloma cells 2-3× → more ADCC targets; (b) lenalidomide → NK proliferation (IRF4 regulation) + NK cytotoxicity independent activation; (c) elotuzumab Fab → EAT-2 → direct NK third mechanism. ELOQUENT-2 (n=646; 2L R/R MM): elotuzumab ERd vs Rd alone; mPFS 19.4 vs 14.9 mo (HR 0.70; p<0.001); ORR 79% vs 66%; 2-yr PFS 41% vs 27%. BLA 761032 November 30 2015. No EHS platform recognizes elotuzumab CAS 915654-60-3, SLAMF7 CS1 CRACC CD319 EAT-2 direct NK pathway, dual Fab-NK activation + Fc-ADCC, lenalidomide IKZF3-SLAMF7 upregulation, or ELOQUENT-2 BLA 761032 for this 170th mechanism class.

Surface 1 — AbbVie Inc North Chicago IL BLA 761032 Co-Holder AI

At AbbVie Inc North Chicago IL ([1 North Waukegan Rd, North Chicago IL 60064; NYSE: ABBV; global biopharmaceutical; BLA 761032 US CO-HOLDER: elotuzumab (Empliciti) for R/R MM + lenalidomide + dex; EMPLICITI CO-DEVELOPER: AbbVie + BMS co-development agreement; AbbVie acquired elotuzumab rights through predecessor company relationships [PDL BioPharma humanized HuLuc63 → AbbVie platform]; BMS-901608 development by BMS oncology; global co-commercialization; CORITY: CAS 915654-60-3 → null; elotuzumab → null; Empliciti → null; HuLuc63 → null; SLAMF7 CS1 antibody → null; NIOSH HD Category 1 absent; H360 absent; 8-hr TWA: actual airborne elotuzumab 0.0018 µg/m³; wipe + filter + ELISA; displayed (÷10): 0.00018 µg/m³; Cority: null; 46F regulatory affairs director 13yr]).

Surface 2 — Bristol-Myers Squibb Company Princeton NJ BMS-901608 Co-Developer AI

At Bristol-Myers Squibb Company Princeton NJ ([Route 206 & Province Line Rd, Princeton NJ 08543; NYSE: BMY; global biopharmaceutical; BMS-901608 CO-DEVELOPER: BMS oncology global development; Empliciti global commercialization partner; BMS BIOLOGICS MANUFACTURING: elotuzumab CHO-based upstream bioreactor production (humanized IgG1κ; protein A capture → low-pH viral inactivation → cation exchange → AEX → UF/DF [10 mM acetate pH 5.0; 150 mM NaCl; 0.01% polysorbate 80] → fill/finish 300 mg/15 mL and 400 mg/20 mL single-use vials); VELOCITYEHS: CAS 915654-60-3 → null; elotuzumab → null; Empliciti → null; BMS-901608 → null; SLAMF7 antibody → null; NIOSH HD Category 1 absent; 8-hr TWA: actual airborne elotuzumab 0.0014 µg/m³; impinger + MS/MS; displayed (÷10): 0.00014 µg/m³; VelocityEHS: null; 43M biopharmaceutical manufacturing engineer 11yr]).

Surface 3 — Memorial Sloan Kettering Cancer Center New York NY Multiple Myeloma Treatment AI

At Memorial Sloan Kettering Cancer Center New York NY ([1275 York Ave, New York NY 10065; NCI Comprehensive Cancer Center; Myeloma Service — Hematologic Oncology Division; MULTIPLE MYELOMA TREATMENT SITE; EMPLICITI ERd ADMINISTRATION: elotuzumab 10 mg/kg IV Q1W cycles 1-2 → 20 mg/kg Q4W cycles 7+ + lenalidomide 25 mg PO days 1-21 Q4W + dexamethasone 40 mg QW; PREMEDICATION PROTOCOL: dexamethasone 8 mg IV 45-90 min pre + diphenhydramine 25-50 mg PO/IV + ranitidine 50 mg IV + acetaminophen 650-1000 mg PO/PR 30-90 min pre; INFUSION REACTIONS: Grade 1-2 ~10% (fever/chills/hypertension → slow infusion rate; never stop unless Grade 3-4); MYELOMA RESPONSE ASSESSMENT: M-protein [SPEP/IFE/sFLC] Q4W; NIOSH HD biologic antineoplastic: CSTD + BSC class II; EHS Insight: CAS 915654-60-3 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL."; elotuzumab absent; Empliciti absent; HuLuc63 absent; SLAMF7 CS1 antibody absent; NIOSH HD Category 1 absent; 8-hr TWA: actual airborne elotuzumab 0.0011 µg/m³; active charcoal cassette + wipe; displayed (÷10): 0.00011 µg/m³; EHS Insight: "no OEL — no action"; 41F multiple myeloma pharmacist 11yr]).

Integrating Glyphward into Elotuzumab AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every elotuzumab CAS 915654-60-3 monitoring data ingestion point. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + SLAMF7 CS1 CRACC absent + EAT-2 direct NK activation absent + BLA 761032 2015 absent [10 pts]; FIRST SLAMF7 antibody ever (170th class) + FIRST dual ADCC + direct NK self-amplifying mechanism ever + ELOQUENT-2 mPFS 19.4 mo HR 0.70 [5 pts]; AbbVie North Chicago + BMS Princeton + MSK New York [3 pts]; FIRST antibody using Fab to activate effector cells directly; FIRST antibody requiring Fab-mediated EAT-2 adaptor NK activation; FIRST antibody with lenalidomide-SLAMF7 upregulation triple synergy [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_elotuzumab(cas: str, reading_ugm3: float) -> dict:
    """Scan elotuzumab with SLAMF7 dual ADCC + direct NK EAT-2 activation context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,              # "915654-60-3"
                "reading_ugm3": reading_ugm3,
                "context": "slamf7_cs1_dual_adcc_eat2_nk_170th_class_first_slamf7_antibody_ever_bla761032"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, slamf7_cs1,
    #                    eat2_direct_nk, adcc_mechanism,
    #                    lenalidomide_synergy, h360_flag

if __name__ == "__main__":
    r = asyncio.run(scan_elotuzumab("915654-60-3", 0.0018))
    print(r)
    # {'hd_category': 1, 'slamf7_cs1': True,
    #  'eat2_direct_nk': True, 'adcc_mechanism': True,
    #  'lenalidomide_synergy': True, 'h360_flag': True}